NASDAQ: XXII
22nd Century Group Inc Stock

$3.05-0.29 (-8.68%)
Updated Feb 7, 2025
XXII Price
$3.05
Fair Value Price
N/A
Market Cap
$1.05M
52 Week Low
$3.04
52 Week High
$581.85
P/E
0x
P/B
0.3x
P/S
-0.27x
PEG
N/A
Dividend Yield
N/A
Revenue
-$10.63M
Earnings
-$39.94M
Gross Margin
41%
Operating Margin
297.54%
Profit Margin
533.3%
Debt to Equity
6.54
Operating Cash Flow
-$15M
Beta
1.35
Next Earnings
Mar 26, 2025
Ex-Dividend
N/A
Next Dividend
N/A

XXII Overview

22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies. The company has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Buffalo, New York.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine XXII's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

F
Value
B
Growth
D
Momentum
C
Sentiment
D
Safety
F
Financials
F
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Tobacco

Industry Rating
D
XXII
Ranked
#6 of 7

Top Ranked Stocks in Industry

View Top Tobacco Stocks

Be the first to know about important XXII news, forecast changes, insider trades & much more!

XXII News

Overview

Due Diligence Score

–
Industry Average (31)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how XXII scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

XXII is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
XXII is good value based on its book value relative to its share price (0.3x), compared to the US Tobacco industry average (7.57x)
P/B vs Industry Valuation
XXII is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more XXII due diligence checks available for Premium users.

Valuation

XXII price to earnings (PE)

For valuing profitable companies with steady earnings

Company
0x
Industry
17.92x
Market
30.7x

XXII price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.3x
Industry
7.57x
XXII is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

XXII's financial health

Profit margin

Revenue
$5.9M
Net Income
-$3.8M
Profit Margin
-125%
XXII's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
XXII's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$26.2M
Liabilities
$22.7M
Debt to equity
6.54
XXII's short-term assets ($15.76M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XXII's short-term assets ($15.76M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XXII's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
XXII's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.0M
Investing
-$70.0k
Financing
$7.1M
XXII's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

XXII vs Tobacco Stocks

TickerZen RatingMarket Cap1d %P/EP/B
XXIID$1.05M-8.68%-0.00x0.30x
GNLND$1.89M-5.37%0.39x0.20x
KAVL–$9.02M-1.48%-0.54x0.67x
ISPRD$264.54M-0.85%-13.74x8.61x
TPBC$1.19B+0.04%24.89x6.40x

22nd Century Group Stock FAQ

What is 22nd Century Group's quote symbol?

(NASDAQ: XXII) 22nd Century Group trades on the NASDAQ under the ticker symbol XXII. 22nd Century Group stock quotes can also be displayed as NASDAQ: XXII.

If you're new to stock investing, here's how to buy 22nd Century Group stock.

What is the 52 week high and low for 22nd Century Group (NASDAQ: XXII)?

(NASDAQ: XXII) 22nd Century Group's 52-week high was $581.85, and its 52-week low was $3.04. It is currently -99.48% from its 52-week high and 0.33% from its 52-week low.

How much is 22nd Century Group stock worth today?

(NASDAQ: XXII) 22nd Century Group currently has 343,402 outstanding shares. With 22nd Century Group stock trading at $3.05 per share, the total value of 22nd Century Group stock (market capitalization) is $1.05M.

22nd Century Group stock was originally listed at a price of $42,119.58 in Jan 26, 2011. If you had invested in 22nd Century Group stock at $42,119.58, your return over the last 14 years would have been -99.99%, for an annualized return of -49.39% (not including any dividends or dividend reinvestments).

How much is 22nd Century Group's stock price per share?

(NASDAQ: XXII) 22nd Century Group stock price per share is $3.05 today (as of Feb 7, 2025).

What is 22nd Century Group's Market Cap?

(NASDAQ: XXII) 22nd Century Group's market cap is $1.05M, as of Feb 9, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

22nd Century Group's market cap is calculated by multiplying XXII's current stock price of $3.05 by XXII's total outstanding shares of 343,402.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.